Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Group psilocybin or MDMA exposure in healthy psychedelic-therapy trainees
ACTRN12622001535763Phase 3Completed
- Sponsor
- Monarch Mental Health Group
- Start
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of psilocybin and midomafetamine in mental disorder (3 arms), sponsored by Monarch Mental Health Group. Primary endpoints: Depression rating scale score, Openness to experience and 1 more. Started Sep 2023; status: completed.
02
Drugs
psilocybinmidomafetamine
03
Conditions
mental disorder
Beyond the preview
Go deeper on ACTRN12622001535763.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12622001535763.